BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 29441070)

  • 1. A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations.
    Toor JS; Rao AA; McShan AC; Yarmarkovich M; Nerli S; Yamaguchi K; Madejska AA; Nguyen S; Tripathi S; Maris JM; Salama SR; Haussler D; Sgourakis NG
    Front Immunol; 2018; 9():99. PubMed ID: 29441070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population-level distribution and putative immunogenicity of cancer neoepitopes.
    Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
    BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico analysis of MHC-I restricted epitopes of Chikungunya virus proteins: Implication in understanding anti-CHIKV CD8(+) T cell response and advancement of epitope based immunotherapy for CHIKV infection.
    Pratheek BM; Suryawanshi AR; Chattopadhyay S; Chattopadhyay S
    Infect Genet Evol; 2015 Apr; 31():118-26. PubMed ID: 25643869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deciphering the selective binding mechanisms of anaplastic lymphoma kinase-derived neuroblastoma tumor neoepitopes to human leukocyte antigen.
    Tian W; Liu X; Wang L; Zheng B; Jiang K; Fu G; Feng W
    J Mol Model; 2021 Apr; 27(5):134. PubMed ID: 33899124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
    Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
    J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection.
    Ebrahimi-Nik H; Michaux J; Corwin WL; Keller GL; Shcheglova T; Pak H; Coukos G; Baker BM; Mandoiu II; Bassani-Sternberg M; Srivastava PK
    JCI Insight; 2019 Jun; 5(14):. PubMed ID: 31219806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
    Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
    Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low HLA binding of diabetes-associated CD8+ T-cell epitopes is increased by post translational modifications.
    Sidney J; Vela JL; Friedrich D; Kolla R; von Herrath M; Wesley JD; Sette A
    BMC Immunol; 2018 Mar; 19(1):12. PubMed ID: 29562882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
    Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A conserved energetic footprint underpins recognition of human leukocyte antigen-E by two distinct αβ T cell receptors.
    Sullivan LC; Walpole NG; Farenc C; Pietra G; Sum MJW; Clements CS; Lee EJ; Beddoe T; Falco M; Mingari MC; Moretta L; Gras S; Rossjohn J; Brooks AG
    J Biol Chem; 2017 Dec; 292(51):21149-21158. PubMed ID: 28972140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neoepitope landscape of breast cancer: implications for immunotherapy.
    Narang P; Chen M; Sharma AA; Anderson KS; Wilson MA
    BMC Cancer; 2019 Mar; 19(1):200. PubMed ID: 30832597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward the prediction of class I and II mouse major histocompatibility complex-peptide-binding affinity: in silico bioinformatic step-by-step guide using quantitative structure-activity relationships.
    Hattotuwagama CK; Doytchinova IA; Flower DR
    Methods Mol Biol; 2007; 409():227-45. PubMed ID: 18450004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metadherin peptides containing CD4(+) and CD8(+) T cell epitopes as a therapeutic vaccine candidate against cancer.
    Dhiman G; Lohia N; Jain S; Baranwal M
    Microbiol Immunol; 2016 Sep; 60(9):646-52. PubMed ID: 27554419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma.
    K Singh V; Werner S; Hackstein H; Lennerz V; Reiter A; Wölfel T; Damm-Welk C; Woessmann W
    Clin Exp Immunol; 2016 Oct; 186(1):96-105. PubMed ID: 27414060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitope distribution in ordered and disordered protein regions - part A. T-cell epitope frequency, affinity and hydropathy.
    Mitić NS; Pavlović MD; Jandrlić DR
    J Immunol Methods; 2014 Apr; 406():83-103. PubMed ID: 24614036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
    Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
    Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics.
    Ade CM; Sporn MJ; Das S; Yu Z; Hanada KI; Qi YA; Maity T; Zhang X; Guha U; Andresson T; Yang JC
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37758652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction profiling of T-cell epitopes with MHC-class I molecules.
    Dash BP; Mukherjee S; Suhas VL; Chandra N
    Protein Pept Lett; 2007; 14(6):557-64. PubMed ID: 17627596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematically benchmarking peptide-MHC binding predictors: From synthetic to naturally processed epitopes.
    Zhao W; Sher X
    PLoS Comput Biol; 2018 Nov; 14(11):e1006457. PubMed ID: 30408041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations.
    Shen M; Chen S; Han X; Hao Y; Wang J; Li L; Chen T; Wang B; Zou L; Zhang T; Zhang W; Han X; Wang W; Yu H; Li K; Liu S; Jin A
    Cancer Immunol Immunother; 2024 Jun; 73(8):150. PubMed ID: 38832948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.